Hypovitaminosis D is suspected to be linked to several types of cancer, metabolic syndrome, cardiovascular disease, and all-cause mortality. This review explores the relationship of vitamin D to blood pressure and hypertension, a major cardiovascular disease risk factor. The literature up to June 2009 was searched without language or time restrictions from MEDLINE and PubMed, and it was supplemented with references from included studies. Ten observational studies and nine randomized control trials concerned with the association between vitamin D and blood pressure were identified and analyzed. Of these, eight observational studies and three randomized control trials supported an inverse association between vitamin D and blood pressure. Current observational studies strongly support an inverse association between vitamin D and blood pressure, but this association has yet to be convincingly supported with randomized control trials. More research is needed to determine the amount of vitamin D supplementation or ultraviolet B irradiation needed to maintain optimal serum 25-hydroxyvitamin D levels and to lower high blood pressure and to determine who can benefit from vitamin D supplementation or ultraviolet B irradiation.
INTRODUCTION
The role that vitamin D plays in regulating calcium and phosphorus and in maintaining bone structure has been known for some time. 1 However, in more recent years, studies have linked vitamin D deficiency to obesity, [2] [3] [4] nonspecific musculoskeletal pain, 5 decreased insulin sensitivity, 4, 6 increased risk of metabolic syndrome, 6 autoimmune diseases such as multiple sclerosis, 7 several types of cancer, [8] [9] [10] [11] cardiovascular disease, 12 all-cause mortality, 13 and more. This review examines published research on the relationship of vitamin D specifically to blood pressure and hypertension, a major cardiovascular disease risk factor.
Vitamin D
There are two types of vitamin D used by the human body, ergocalciferol (vitamin D 2 ) and cholecalciferol (vitamin D 3 ), but both are inactive precursors to the same active metabolite, 1,25-dihydroxyvitamin D (1,25- [OH] 2 D 3 ), also known as calcitriol. 1 Main dietary sources of vitamin D include fatty fish, 14 foods fortified with vitamin D such as milk 1, 15 and cereal, 1 and vitamin D supplementation. 7 Cholecalciferol is also produced naturally by exposing the skin to ultraviolet B (UV-B) in sunlight, wherein UV-B photons with energies between 290 and 315 nm are absorbed by 7-dehydrocholesterol in the skin to form previtamin D 3 . 1, 16 Previtamin D 3 is then quickly converted into vitamin D 3 , which can then be hydroxylated at its 25th and first carbons by 25-hydroxylase (mainly found in the liver) and 1a-hydroxylase (mainly found in the kidney), respectively, to form the active vitamin D metabolite. 16, 17 Although 1,25-(OH) 2 D is the active vitamin D metabolite, 25-hydroxyvitamin D (25[OH]D) is a more accurate marker of vitamin D status than 1,25-(OH) 2 D. 25(OH)D has a half-life of days to weeks as opposed to the 4-to 6-hour half-life of 1,25-(OH) 2 D, yet it also reflects the combined effects of ergocalciferol and cholecalciferol. 1 1,25-(OH) 2 D is also a poorer marker of vitamin D status because in conditions of moderately low 25(OH)D (serum levels of 20-40 nmol/L), the resulting increased parathyroid hormone stimulates 1a-hydroxylase activity in the kidney, producing an increased level of 1,25-(OH) 2 D. 18 Optimal serum vitamin D levels have been established based on the level of 25(OH)D that keeps parathyroid hormone at a minimum steady state, which has been determined to be approximately 75 nmol/L (30 ng/mL). 11 It is becoming more apparent that insufficient vitamin D status is an endemic problem. It is especially seen in blacks and other populations with dark skin tones, whose cholecalciferol production is limited as a result of increased amounts of melanin in their skin, 12, 18, 19 in the elderly, whose decreased amounts of 7-dehydrocholesterol limit the production of cholecalciferol, 12, 20, 21 and in people living at latitudes far away from the equator, because their lack of exposure to UV-B also limits the production of cholecalciferol. 19 
METHODS
The literature up to June 2009 was searched without language or time restrictions from MEDLINE and PubMed. Searches were performed using combinations of the following key words: ''vitamin D,'' ''blood pressure,'' ''hypertension,'' ''control trial,'' and ''observational study.'' The initial searches resulted in abstracts for a total of 790 articles. These abstracts were read for their relevance, and 52 articles were reviewed in detail for possible inclusion. Reference lists of relevant articles were also skimmed for possible omissions from the initial searches.
Randomized control trials (RCTs) and observational studies were selected for inclusion in this review if they used 25(OH)D as the marker for vitamin D status (if serum levels were measured), if they were human studies, and if they examined a possible relationship between vitamin D and blood pressure. Studies that only used 1,25-(OH) 2 D as the vitamin D marker and animal studies were excluded. For control trials, only double-blinded, randomized trials that had similar treatment and control groups at baseline were selected for inclusion. The types of interventions that were allowed include cholecalciferol, ergocalciferol, alphacalcidol (a synthetic analog to calcitriol), and UV-B.
RESULTS
The selection criteria resulted in a total of 10 observational studies, depicted in Table 1 , and nine RCTs, depicted in Table 2 , to be included in this review.
There were a total of 72,970 participants included in the 10 observational studies. As seen in Table 1 , eight of the 10 observational studies supported an inverse association between vitamin D intake or serum 25(OH)D levels and blood pressure. 12, 15, [20] [21] [22] [23] [24] [25] Of these eight studies, four linked insufficient serum 25(OH)D levels or vitamin D intake to hypertension specifically, 12, 15, 20, 22 two linked it to blood pressure in general, 21, 23 one linked it to systolic blood pressure (SBP) and diastolic blood pressure (DBP), 24 and one linked it to SBP only. 25 Two of the studies had statistically significant data linking only dietary vitamin D intake to blood pressure, and not supplemental intake of vitamin D, indicating possible confounding situations. 15, 24 The nine RCTs depicted in Table 2 included a total of 821 participants. Six of the RCTs measured serum 25(OH)D levels at baseline and after the supplementation period was complete, and for each RCT, the mean serum 25(OH)D for the supplemental group increased by a significant amount compared with the placebo group. [26] [27] [28] [29] [30] [31] Of these six RCTs, the trials by Sugden et al 27 and Pfeifer et al 29 saw significant reductions in SBP in the supplemental group as compared with the control group; Zittermann et al, 26 Schleithoff et al, 28 and Scragg et al 30 saw no significant reductions in either SBP or DBP between the two groups; and Krause et al 31 did not provide data comparing SBP or DBP between the two groups.
Of the three RCTs that did not measure serum 25(OH)D levels, Lind et al 32 saw significant reductions in both SBP and DBP between the supplemental and control groups when analyzing data from only patients with presupplemental blood pressures 150/90 mmHg or greater, but Myrup et al 33 and Lind et al 34 saw no significant reductions in either SBP or DBP between the two groups.
Only two studies, those by Scragg et al 30 and Myrup et al, 34 recruited healthy individuals for their studies. The other seven trials recruited patients with various underlying health problems, as depicted in Table 2 .
DISCUSSION
Eight of the 10 observational studies supported the idea that serum 25(OH)D levels are inversely related to blood pressure. The small study done by Lind et al 35 is one of the two studies that did not support such an association. In this study, only 45 men were selected for inclusion from the larger cohort, and only 34 of those 45 had their vitamin D metabolites measured as a result of technical difficulties. This small sample size makes the study somewhat unreliable, especially compared with the larger studies included in this review, 12, 15, 20, 21, 23 which analyzed data from thousands, if not tens of thousands, of individuals. 
Cross-sectional study
Data from a blood sample, physical examination, and an average of three BP measurements were gathered and analyzed for associations Black men and women had significantly lower 25(OH)D levels at every level of blood pressure than did whites (P , 0.01); in the white population tested, an inverse association between serum 25(OH)D levels and blood pressure existed (P , 0.001); similar data were unable to be obtained in the black population tested as a result of the small number of black participants with sufficient vitamin D levels † (8%) Kim (6) Vitamin D for Blood Pressure Homeostasis e223 Women in the 25-35 age group showed an inverse association between dietary vitamin D intake and SBP (P = 0.0016); women in the 55-80 age group who consumed less than the RDA k for calcium and vitamin D had significantly higher SBP than women that met the RDA for at least one of them (P = 0.0371) *Definitions of serum 25(OH)D levels: vitamin D deficiency less than 30 ng/mL, sufficiency 30 ng/mL or greater; 65.7% of total women were vitamin D-deficient. †Definitions of serum 25(OH)D levels: vitamin D deficiency less than 50 nmol/L, insufficiency = 50-80 nmol/L, sufficiency 80 nmol/L or greater. ‡Defines hypertension as: SBP 140 mmHg or greater, DBP 90 mmHg or greater, or use of antihypertensive medication. §Hypertension defined as self-reported SBP 140 mmHg or greater, DBP 90 mmHg or greater, physician diagnosis of hypertension, or use of antihypertensive medication. k RDA: 400 IU/day for vitamin D and 800 mg/day for calcium. BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; SFFQ, semiquantitative food frequency questionnaire; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; BMI, body mass index; RDA, recommended daily allowance. To convert 25(OH)D levels from nmol/L to ng/mL, divide by 2.5; to convert mg to IU, multiply by 40. The supplemental group had an average reduction of SBP/DBP of 9.0/ 3.2 mmHg (P , 0.01 and P = 0.02, respectively); men in the supplemental group who had a pre-supplement BP 150/90 mmHg or greater had significantly greater reductions of both SBP and DBP compared with the average for the supplemental group as a whole; the average reduction for this group of hypertensive men was -21/-7 mmHg (P , 0.01 and P , 0.05, respectively); the decreases in SBP and DBP between the supplemental and control groups were only significant when just patients with pretreatment BP 150/90 mmHg or greater were included *Baseline 25(OH)D levels less than 50 nmol/L. †Combination tablet: 2 mg estradiol and 1 mg estriol for Days 1-12; 2 mg estradiol, 1 mg estriol, and 1 mg norethindrone for Days 13-22; 1 mg estradiol and 0.5 mg estriol for Days 23-28. BMI, body mass index; SBP systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure. To convert 25(OH)D levels from nmol/L to ng/mL, divide by 2.5; to convert mg to IU, multiply by 40.
The other study that did not support an association between serum 25(OH)D levels and blood pressure is the study by Michos et al. 36 There are two disadvantages to this study that prevent it from providing strong data in regard to vitamin D and blood pressure. First, the main goal of the study was to examine the relationship between serum 25(OH)D levels and C-reactive protein, coronary artery calcification, and carotid intimal medial thickness rather than with hypertension itself. The data on hypertension were only used as an adjustment factor for the inflammation and subclinical vascular disease markers. Second, 85.9% of this study population had serum 25(OH)D levels less than 30.0 ng/mL, which became a problem when dividing up their study population into quintiles of serum 25(OH)D levels. In doing so, Michos et al used the range of 26.2 to 49.1 ng/mL as their fourth and highest quintile. The problem with this is that it includes vitamin D-insufficient (less than 30.0 ng/mL) and vitamin D-sufficient (30.0 ng/mL or greater) individuals in the same category, making it challenging to draw useful conclusions on the association of vitamin D and blood pressure. 36 Not all of the eight studies that support the inverse association of vitamin D and blood pressure should be weighted equally, however. The two studies 15, 24 that support an association only in regard to dietary intake of vitamin D, and not of supplemental intake of vitamin D, indicate possible confounding situations and should therefore be given lesser worth than the other six studies.
The remaining six studies 12, [20] [21] [22] [23] 25 include a total of 42,996 participants and provide strong enough data to recommend that RCTs involving the supplementation of vitamin D and analysis of its effects on blood pressure should be done.
There were many varying factors between the published RCTs found for this review, however, making it difficult to draw any convincing conclusions. The strongest trials found were those that measured serum 25(OH)D levels at baseline and after the supplementation period and in which the patients in the supplemental group were vitamin D-sufficient (mean 25[OH]D levels greater than 30 ng/mL or greater than 75 nmol/L) after the supplementation period. These criteria indicate that the strongest trials found were those by Zittermann et al, 26 Schleithoff et al, 28 and Krause et al. 31 The RCT performed by Zittermann et al 26 compared weight loss and cardiovascular risk factors between a group of subjects that received 83.3 mg (3332 IU) cholecalciferol daily with a group of similar subjects that received a daily placebo over a timeframe of 12 months. Zimmerman's primary goal was to measure weight loss and fat loss, however, and measuring the effects on cardiovascular risk factors was a secondary goal. Because of this, blood pressure was only measured once at the beginning of the study and once at the end of the study, making the accuracy of the results included here somewhat questionable.
Another possible confounding factor in the Zittermann trial is the result of the patient population used. The patients used in this trial were all overweight with a body mass index greater than 27 kg/m, 26 and many studies have shown an inverse association between serum 25(OH)D levels and adiposity. 2, 3 It has been hypothesized that this inverse relationship could be the result of an altered release of vitamin D 3 from the skin into the circulation or to decreased bioavailability of vitamin D 3 because of its sequestration in adipose tissue. Even if either hypothesis is correct, an increased dosage of vitamin D supplementation should reverse some of these effects. 3 It is possible, therefore, that the patients in the Zittermann trial might not have received a large enough dose of cholecalciferol to compensate for the extra adipose tissue in these patients to allow otherwise expected changes in blood pressure to be seen.
The trial by Schleithoff et al 28 also failed to show an association between serum 25(OH)D levels and blood pressure, but again, this might be the result of the patient population used for the trial. These patients all had congestive heart failure, so it is possible that the vascular and systemic effects of this disease prevented any expected benefit from cholecalciferol supplementation from being seen.
The trial by Krause et al 31 was the only included study to use UV-B as its intervention rather than supplementation with a vitamin D metabolite. This trial is of extra interest because the patients used in this study had untreated, mild hypertension. This trial supported an association between low plasma 25(OH)D levels and hypertension, because the UV-B irradiation resulted in a nearly 300% increase in plasma 25(OH)D levels and a significant reduction in both SBP and DBP. The limitation of this study was its small sample size of only 17 patients.
The study by Pfeifer et al 29 would not be included as a strong study based on the criteria listed, because the patients in the supplemental group had a mean serum 25(OH)D 3 level of only 64.84 nmol/mL after the supplementation period. However, this study might be an exception to these criteria because the patients needed a baseline serum 25(OH)D 3 level less than 50 nmol/L to be included in this study, and they did see a 72% increase in mean serum 25(OH)D 3 level at trial completion (P , 0.01). It is possible that this group saw a significant reduction in SBP that was not mirrored in DBP because although their serum 25(OH)D 3 levels did increase significantly, they did not increase to a level that would classify them as being vitamin D-sufficient. Their vitamin D insufficiency at trial completion could have prevented any results in DBP from being seen.
In the other six trials, various factors prevent each one from providing strong data on a possible relationship between vitamin D and blood pressure. The two trials by Lind et al 32, 34 and the trial by Myrup et al 33 fail to measure serum 25(OH)D levels. In addition, each of these supplemental groups received 1 mg/day or less of a vitamin D metabolite. The recommended daily allowance for vitamin D is 10 mg (400 IU), 25 so it is likely that this low level of supplementation would not alter serum 25(OH)D levels enough to produce significant effects on blood pressure, even if a correlation between the two existed.
The trials by Sugden et al 27 and Scragg et al 30 both gave one dose of 2.5 mg (100,000 IU) to their supplemental groups. Although both of these trials hoped to find therapeutic effects of vitamin D, other research has supported a toxic role of vitamin D if taken at or in excess of 10,000 IU per day. 11, 37 This toxic dose was only given once in these two trials, however, so whether they actually had toxic or therapeutic effects is difficult to determine.
It is interesting to note that the patients in the supplemental group of the trial by Sugden et al, 27 who were vitamin D-insufficient at the beginning of the trial, saw a significant reduction in SBP, whereas the healthy patients in the trial by Scragg et al 30 did not. This could support the idea that supplementation with vitamin D is more effective when given to patients with insufficient or deficient levels of serum 25(OH)D than to patients that are already vitamin D-sufficient. This idea is supported in other research as well, including a study by Carbone et al, which found that increases in serum 25(OH)D with UV-B treatment were a function of baseline serum 25(OH)D levels and were most effective with low baseline levels. 38 However, there was a nearly significant difference in SBP between the treatment and control groups of the Sugden trial at baseline (145 6 9.2 versus 137 6 14.1 mmHg, P = 0.07), which could also be responsible for this difference. 27 
Limitations
Like with any systematic review, it is possible that relevant articles and trials escaped our searches or inclusions. We were also limited to published articles only.
CONCLUSIONS
It is evident that hypovitaminosis D is a global problem, especially in black and Hispanic populations, 12, 18, 19 in the elderly, 12, 20, 21 and in those people living at extreme latitudes. 19 Current observational studies strongly support an inverse association between serum 25(OH)D levels and blood pressure, but this association has yet to be convincingly supported with RCTs. More research is needed to determine the amount of vitamin D supplementation or UV-B irradiation needed to maintain optimal serum 25-hydroxyvitamin D levels and to lower high blood pressure and to determine who can benefit from vitamin D supplementation or UV-B irradiation.
